Interest in FASN-driven lipid signaling as a target for therapeutic intervention stemmed from findings more than a decade ago that tumor cells show reduced growth and viability upon targeted FASN suppression [8, 9, 11–14]. This evidence concerns the gene FASN and neoplasm.